They will conduct a randomized, controlled, parallel group trial of the effectiveness of a new minimally invasive intervention for disabling shoulder pain in wheelchair users with chronic spinal cord injury and overuse injuries - autologous micro-fragmented adipose tissue injection.
For the study, 28 participants will be randomly assigned to receive an ultrasound-guided injection into the shoulder joint that contains either: 1) autologous, micro-fragmented adipose tissue; or 2) corticosteroid (triamcinolone acetonide). All participants will then undergo a standardized home exercise program, and periodic follow-up for 6 months after the injection, including physical examination and imaging studies.
Adipose tissue is a readily accessed source of mechanical, bioactive and bioavailable elements. The adipose used for the injection is obtained using the Lipogems system. A person's own fat is harvested and processed by the Lipogems system to yield autologous, micro-fragmented adipose tissue that is then injected into the shoulder joint under ultrasound guidance. These procedures are performed by Dr. Malanga, an expert in orthopedic and sports-related injuries.
The new intervention may expand treatment options for wheelchair users with intractable shoulder pain and limited range of motion. "If conservative treatments such as medications and physical therapy fail, then surgery is often the only remaining option," said Dyson-Hudson. "Surgery, however, involves many months of recovery, which can have a significant impact on quality of life in persons who rely on their shoulders for everyday activities and independence," he explained, "and their risk is especially high for poor outcomes."
MEDICA-tradefair.com; Source: Kessler Foundation